Table I.
Studies, analysis method, number of malignant lesions and results of BRAF detection in FNA pre-operative.
| First author (ref.) | Year | Analysis method | Number of malignant lesions / BRAF+
|
|||||
|---|---|---|---|---|---|---|---|---|
| PTC | FVPTC | FTC | HCC | ATC | MTC | |||
| Salvatore et al (17) | 2004 | PCR - direct sequencing/SSCP | 47/23 | 22/3 | ||||
| Cohen et al (22) | 2004 | PCR direct sequencing and Mutector assay | 27/18 | 27/4 | 2/0 | 1/0 | 1/1 | 1/0 |
| Hayashida et al (13) | 2004 | PCR - RFLP | 21/5 | |||||
| Xing et al (23) | 2004 | PCR - colorimetric mutation detection method | 16/7 | 5/0 | 1/0 | |||
| Domingues et al (24) | 2005 | PCR - Direct sequencing | 11/3 | 1/0 | 1/0 | |||
| Chung et al (25) | 2006 | PCR - Direct sequencing | 107/92 | 3/0 | 2/1 | |||
| Jin et al (26) | 2006 | PCR - Direct sequencing, colorimetric Mutector assay, LightCycler PCR and allele-specific PCR | 45/29 | 13/2 | ||||
| Rowe et al (16) | 2006 | LightCycler PCR | 19/3 | |||||
| Pizzolanti et al (27) | 2007 | Real-time allele-specific-PCR | 14/10 | 2/1 | 1/0 | |||
| Sapio et al (28) | 2007 | PCR-MASA | 6/4 | 1/0 | 1/0 | |||
| Sapio et al (18) | 2007 | PCR-MASA | 21/10 | 5/0 | ||||
| Kim et al (29) | 2008 | PCR-Pyrosequencing | 73/63 | 2/0 | 3/0 | 1/0 | 1/0 | |
| Zatelli et al (4) | 2009 | PCR-Direct sequencing/RFLP | 58/41 | 16/6 | 7/0 | 1/1 | 6/0 | |
| Nikiforov et al (15) | 2009 | LightCycler PCR/FMCA | 38/18 | 6/0 | 2/0 | 2/0 | ||
| Moon et al (30) | 2009 | PCR - Direct sequencing | 84/42 | |||||
| Marchetti et al (31) | 2009 | PCR - Direct sequencing | 89/59 | 2/0 | ||||
| Bentz et al (32) | 2009 | LightCycler PCR/FMCA | 24/18 | 16/6 | ||||
| Kwak et al (21) | 2009 | PCR - Direct sequencing | 339/213 | |||||
| Xing et al (11) | 2009 | PCR - Colorimetric mutation detection method | 149/68 | 41/5 | ||||
| Yip et al (14) | 2009 | PCR-FMCA | 44/31 | |||||
| Kim et al (33) | 2009 | PCR - Pyrosequencing | 101/88 | |||||
| Jo et al (34) | 2009 | PCR - Pyrosequencing | 40/30 | |||||
| Hwang et al (12) | 2010 | PCR - Direct sequencing and allele-specific PCR | 135/106 | |||||
| Lin et al (35) | 2010 | PCR - Direct sequencing | 61/21 | |||||
| Dujardin et al (36) | 2010 | PCR - Direct sequencing | 10/7 | |||||
| Girlando et al (37) | 2010 | PCR - Direct sequencing | 44/34 | 16/9 | ||||
| Musholt et al (38) | 2010 | PCR - MASA | 22/9 | 4/0 | 1/0 | 1/0 | ||
| Kim et al (39) | 2010 | DPO-based multiplex PCR | 263/221 | 4/0 | 1/0 | |||
| Guo et al (40) | 2010 | PCR - Direct sequencing | 8/4 | |||||
| Kwak et al (41) | 2010 | DPO-Based Multiplex PCR | 107/86 | 2/1 | ||||
| Ohori et al (42) | 2010 | LightCycler PCR | 20/3 | |||||
| Moses et al (43) | 2010 | PCR - Direct sequencing | 70/20 | 19/3 | 8/0 | 2/0 | 1/0 | 1/0 |
| Cantara et al (8) | 2010 | PCR - Direct sequencing | 74/33 | 3/0 | 1/0 | |||
| Kim et al (44) | 2011 | PCR- Pyrosequencing | 169/154 | 4/0 | ||||
| Yeo et al (45) | 2011 | PCR- Pyrosequencing | 175/95 | 7/4 | 6/0 | 4/0 | ||
| Adeniran et al (46) | 2011 | PCR - Direct sequencing/SSCP | 60/40 | |||||
| Pelizzo et al (47) | 2011 | PCR - Direct sequencing/MASA | 141/98 | 16/0 | ||||
FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; HCC, Hürthle cell carcinoma; ATC, anaplastic thyroid carcinoma; MTC, medullary thyroid carcinoma; PCR, polymerase chain reaction; MASA, mutant allele-specific amplification; DPO, dual-priming oligonucleotide; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformational polymorphism; FMCA, fluorescence melting curve analysis.